The objective of this contract is to develop a novel HIV vaccine CO-delivery system: an injectable thermosensitive hydrogel encapsulating polyrotaxane (PRX)-based SARNA (PRX-SARNA) nanoparticles and…
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93020C00011
- Awardee
-
Zymeron Corporation UEI GAMMMRQ6QMN1
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Solicitation · SBIRPHS20201 · Posted Jun 21, 2019
- Novel Nanoparticle-in-Hydrogel Co-Delivery of Adjuvanted saRNA as HIV Vaccine Award Notice · Posted Jun 16, 2020
- Contract value 100% obligated
- $300,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 7 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Durham, NC 27709, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $300,000 |
About this award
This SBIR Phase I contract from the National Institutes of Health and National Institute of Allergy and Infectious Diseases aims to develop a novel HIV vaccine co-delivery system. Zymeron Corporation will receive $300,000 to create an injectable thermosensitive hydrogel encapsulating polyroxatane-based self-amplifying RNA nanoparticles and GM-CSF cytokine adjuvant for targeted delivery. The research will take place in Research Triangle Park, North Carolina over approximately 22 months. This total small business set-aside award responds to the NIH/CDC SBIR solicitation seeking proposals for biomedical research and development related to cancer, opioids, and environmental health technologies.
Description
The objective of this contract is to develop a novel HIV vaccine CO-delivery system: an injectable thermosensitive hydrogel encapsulating polyrotaxane (PRX)-based SARNA (PRX-SARNA) nanoparticles and cytokine adjuvant GM-CSF for targeted delivery to a
Quick answers
Who was awarded contract 75N93020C00011?
75N93020C00011 was awarded to Zymeron Corporation by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 1, 2020.
How much is contract 75N93020C00011 worth?
The government has obligated $300,000 on 75N93020C00011.
Was contract 75N93020C00011 competed?
The extent of competition for 75N93020C00011 was full and open competition after exclusion of sources. The government received 7 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award